丁香树脂醇双葡萄糖苷 | 66791-77-3

• 物质功能分类: 生物化工 - 提取物
• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 木脂素苷
• 中文名称: 丁香树脂醇双葡萄糖苷
• 英文名称: liriodendrin
• 英文别名: Syringaresinol-di-O-glucoside；(2S,3R,4S,5S,6R)-2-[4-[(3R,3aS,6R,6aS)-6-[3,5-dimethoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 66791-77-3
• 化学式: C₃₄H₄₆O₁₈
• 分子量: 742.728
• InChiKey: FFDULTAFAQRACT-NYYYOYJKSA-N

物化性质

• 沸点：
  935.7±65.0 °C(Predicted)
• 密度：
  1.474±0.06 g/cm3 (20 ºC 760 Torr)
• 溶解度：
  溶于甲醇和水

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  52
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  254
• 氢给体数：
  8
• 氢受体数：
  18

安全信息

• WGK Germany：
  3

制备方法与用途

用途

丁香树脂醇双葡萄糖苷是一种黄酮类化合物，已被证实具有抗肿瘤作用，并且对治疗骨癌也有益。该物质通过葡萄糖醛酸化代谢，可能是因为它能够抑制粘蛋白基因表达并增加原儿茶酸水平。此外，在培养细胞中，该化合物还被证明具有细胞毒性作用，能够诱导细胞凋亡和细胞死亡。同时，丁香树脂醇双葡萄糖苷也是一种有效的肝微粒体抑制剂，可以抑制代谢反应。

生物活性

丁香树脂醇双葡萄糖苷是从竹叶中提取的天然化合物。

文献信息

• [EN] COMPOSITION CONTAINING AN ETHYL ACETATE SOLUBLE EXTRACT FROM KALOPANAX PICTUS NAKAI AND KALOPANAXSAPONIN A DERIVATIVES ISOLATED THEREIN FOR PROTECTING AND TREATING INFLAMMATORY AND RHEUMATIC DISEASE<br/>[FR] COMPOSITION CONTENANT UN EXTRAIT SOLUBLE D'ACETATE D'ETHYLE PRODUIT A PARTIR DE KALOPANAX PICTUS NAKAI, ET DERIVES DE KALOPANAXSAPONIN A ISOLES DUDIT EXTRAIT POUR PREVENIR OU TRAITER UNE MALADIE INFLAMMATOIRE OU RHUMATISMALE
  申请人：LEE EUN-BANG

  公开号：WO2003099305A1

  公开（公告）日：2003-12-04

  The present invention is related to an ethyl acetate soluble extract from Kalopanax pictus Nakai, which shows anti-inflammatory and anti-rheumatic activities.The present invention provides a pharmaceutical composition comprising above ethyl acetate extract from Kalopanax pictus Nakai and kalopanaxsaponin A derivatves isolated therein for treating and preventing inflammatory and rheumatic diseases.

  本发明涉及一种可溶于乙酸乙酯的刺五加（Kalopanax pictus Nakai）提取物，该提取物具有抗炎和抗风湿活性。本发明提供了一种药物组合物，包括上述从刺五加（Kalopanax pictus Nakai）中提取的乙酸乙酯提取物和分离其中的刺五加皂苷A衍生物，用于治疗和预防炎症和风湿性疾病。
• IMPROVED DOSAGE FORM CONTAINING EXTRACT FROM BARK OF LIRIODENDRON TULIPIFERA AS ACTIVE INGREDIENT
  申请人：Cho Dang Pharm. Co., Ltd.

  公开号：EP2815742A1

  公开（公告）日：2014-12-24

  The present invention relates to an improved dosage form containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of Liriodendron tulipifera and, more specifically, to a dosage form for treating the gastrointestinal tract, the dosage form containing, as active ingredients, epitulipinolide and costunolide, which are the active ingredients of the extract from the bark of Liriodendron tulipifera.

  本发明涉及一种改进剂型，该剂型含有从 Liriodendron tulipifera 树皮中提取的 epitulipinolide 和 costunolide 作为活性成分，更具体地说，涉及一种用于治疗胃肠道的剂型，该剂型含有 epitulipinolide 和 costunolide 作为活性成分，它们是从 Liriodendron tulipifera 树皮中提取的活性成分。
• METHOD FOR EXTRACTING TREATMENT INGREDIENTS FOR GASTROINTESTINAL DISEASES FROM BARK OF LIRIODENDRON TULIPIFERA
  申请人：Cho Dang Pharm. Co., Ltd.

  公开号：EP2815758A1

  公开（公告）日：2014-12-24

  The present invention relates to a method for extracting treatment ingredients for gastrointestinal diseases from the bark of Liriodendron tulipifera, the treatment ingredients containing epitulipinolide and costunolide as active ingredients, and to a therapeutic agent for gastrointestinal diseases, containing epitulipinolide and costunolide extracted using said method.

  本发明涉及一种从 Liriodendron tulipifera 树皮中提取胃肠道疾病治疗成分的方法，该治疗成分含有作为活性成分的表美国鹅掌楸内酯（epitulipinolide）和美国鹅掌楸内酯（costunolide）；本发明还涉及一种胃肠道疾病治疗剂，该治疗剂含有用上述方法提取的表美国鹅掌楸内酯（epitulipinolide）和美国鹅掌楸内酯（costunolide）。
• PHARMACEUTICAL COMPOSITION CONTAINING AS ACTIVE INGREDIENT EXTRACT FROM BARK OF LIRIODENDRON TULIPIFERA
  申请人：Cho Dang Pharm. Co., Ltd.

  公开号：EP2815759A1

  公开（公告）日：2014-12-24

  The present invention relates to a pharmaceutical composition containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of Liriodendron tulipifera. More specifically, the present invention relates to a pharmaceutical composition for treating the gastrointestinal tract, the composition containing, as active ingredients, epitulipinolide and costunolide, which are the active ingredients of the extract from the bark of Liriodendron tulipifera, and to the use thereof as a therapeutic agent for gastrointestinal diseases.

  本发明涉及一种药物组合物，其活性成分是从 Liriodendron tulipifera 树皮中提取的 epitulipinolide 和 costunolide。更具体地说，本发明涉及一种治疗胃肠道的药物组合物，该组合物含有表美国鹅掌楸树皮提取物的有效成分表美国鹅掌楸内酯和木香烃内酯作为有效成分，并涉及其作为胃肠道疾病治疗剂的用途。
• METHOD FOR SEPARATING EIGHTEEN COMPONENTS IN TRADITIONAL CHINESE MEDICINE COMPOSITION
  申请人：Shijiazhuang Yiling Pharmaceutical Co., Ltd.

  公开号：EP3680248A1

  公开（公告）日：2020-07-15

  The invention belongs to the field of quality analysis and control of traditional Chinese medicine, and provides a method for separating eighteen components in a traditional Chinese medicine composition, comprising: (1) preparing the traditional Chinese medicine composition into a total extract of the traditional Chinese medicine composition, separating by resin through sequentially eluting with water, 10% ethanol and 30% ethanol, and collecting the 30% ethanol eluate to obtain a 30% ethanol extract; (2) adding the 30% ethanol extract to a reverse phase silica gel ODS-AQ-HG, and separating in a medium pressure separation column to obtain differently numbered elution dry pastes; (3) dissolving the differently numbered elution dry paste with 30% methanol as a solvent, and passing the solution through a 0.45 µm microporous membrane, carrying out a primary separation by high performance liquid chromatography and collecting chromatographic peaks with different retention times, and further purifying by high performance liquid chromatography; finally obtaining the components of eighteen components. The separation method of the present invention enables in-depth study of the chemical components of a pharmaceutical composition.

  本发明属于中药质量分析与控制领域，提供了一种分离中药组合物中十八种成分的方法，包括：(1)将中药组合物制备成中药组合物的总提取液，通过树脂依次用水、10%乙醇和30%乙醇洗脱分离，收集30%乙醇洗脱液，得到30%乙醇提取液；(2) 将 30%乙醇提取液加入反相硅胶 ODS-AQ-HG，在中压分离柱中分离，得到不同编号的洗脱干膏； (3) 以 30%甲醇为溶剂溶解不同编号的洗脱干膏，溶液通过 0.45 µm的微孔膜，用高效液相色谱进行一级分离，收集不同保留时间的色谱峰，再用高效液相色谱进一步纯化；最后得到十八种组分的组分。本发明的分离方法可以深入研究药物组合物的化学成分。